JAK inhibitors for better management of rheumatic diseases

Speciality: Rheumatology


Speaker:

Prof. Anand N. Malaviya, | MD, FRCP (Lond.) Master ACR & APLAR, FACP, FICP, FAMS, FNASc

Dr Indrajit Agrawal | MD MRCP HOD Rheumatology

Dr Sanjiv Kapoor | MD, DM

Description:

A warm welcome to all the medical professionals in this interesting session of pioneering JAK science. We have Prof. Anand N. Malaviya, Dr Indrajit Agrawal, and Dr Sanjiv Kapoor to lead the session.

Immunological pathways play a crucial role in disease management especially in the case of rheumatological disease. Managing rheumatic diseases often becomes difficult and needs specialized attention which can be gained from this webinar.

The webinar will help in gaining important insights on JAK or Janus Kinase's family. The family includes Jak1, Jak2, Jak3, and Tyk2 which are involved in cell growth, development, and differentiation of the cells.

Get detailed information on the pathways involving JAK and how the JAK inhibiting drugs (tofacitinib) acts in controlling the progression of rheumatic diseases from this session.   

Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Medicaid expansion tied to smaller declines in early-stage cancer detection

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot